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“Life is like riding a bicycle.  
To keep your balance, you must keep moving.” 
 
Albert Einstein  
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Abstract 
Human ovarian cancer is the seventh most common tumour in women worldwide and 
the leading cause of death from gynaecological cancers. Nowadays, there is strong 
evidence that stress affect cancer progression and patient survival. However, the 
underlying mechanisms of this association are poorly understood. The catecholamines 
(CA), adrenaline (AD) and noradrenaline (NA), are released in response to stress, 
exerting their effects through interaction with adrenergic receptors (AR) termed α and 
β. β-AR expression has been identified on several ovarian cancer cells. The activation of 
these receptors triggers several pathways that alter tumour microenvironment, being 
associated to carcinogenesis and tumour progression. β-blockers have a long history of 
use for treatment of arrhythmia, hypertension, anxiety, and heart failure treatment, 
among others. Epidemiological studies show that β-blockers are associated with a 
decrease of cancer mortality and studies about the efficiency of β-AR as a possible 
treatment for cancer are acquiring strength. The effects of several β-blockers with 
distinct intracellular target profiles in human ovarian cancer cells SKOV-3 biology were 
investigated. Cellular proliferation and migration ability after exposure to the agonists 
AD, NA and isoprenaline (ISO) and the antagonists propranolol, carvedilol, atenolol and 
ICI 118,551 per se, or combined with each other, was investigated. AD was able to 
significantly increase the proliferation of SKOV-3 cells, ISO induced a tendency to 
increase proliferation, whereas NA had no effect. Our results suggest that β-blockers 
reduce SKOV-3 cells proliferation, but, similarly to the tested agonists, have no effect on 
SKOV-3 migration. This study might contribute to elucidate which are the most effective 
β-blockers in reverting CA induced proliferative effects in ovarian cancer cells and, 
consequently, to be used as promising strategies in cancer treatment.  
 
 
Keywords: Stress, catecholamines, adrenergic receptors, β-blockers, SKOV-3, 
proliferation, migration. 
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Resumo 
O cancro do ovário é o sétimo cancro mais comum nas mulheres em todo o mundo e 
aquele que apresenta uma maior taxa de mortalidade de entre os cancros ginecológicos. 
A resposta ao stresse conduz à ativação de dois sistemas neurohumorais, o eixo 
hipotálamo-hipófise-suprarrenal e o sistema simpatoadrenomedular, que libertam 
cortisol e catecolaminas (CA), respetivamente, exercendo um papel crucial na função 
cardiovascular e no metabolismo energético. No entanto, esses sistemas, sob influência 
dos padrões de vida atual, por exemplo quando repetidamente ativados por longos 
períodos de tempo, podem deixar de ter uma ação adaptativa e conduzir a doença. De 
acordo com isto, fortes evidências sugerem que o stresse crónico está associado à 
progressão do cancro e também à taxa de sobrevivência. No entanto, os mecanismos 
envolvidos na ligação entre a exposição ao stresse e os efeitos na biologia tumoral são 
ainda mal conhecidos. As CA, adrenalina (AD) e noradrenalina (NA), como referido 
acima, são libertadas a partir do sistema simpatoadrenomedular em resposta ao stresse, 
exercendo os seus efeitos através da interação com recetores adrenérgicos do tipo α e 
β. Os recetores adrenérgicos, preferencialmente os do tipo β, estão expressos em várias 
células de cancro do ovário. A ativação destes recetores por sua vez promove a ativação 
de várias cascatas de sinalização que alteram o microambiente tumoral, estando 
associadas à progressão dos tumores e a eventos como a carcinogénese. Na verdade, 
vários estudos mostraram a relação entre os recetores adrenérgicos β e parâmetros de 
dinâmica celular como a angiogénese, a proliferação, a apoptose, a inflamação, a 
resposta imunitária, a migração, a invasão e a formação de metástases. Os bloqueadores 
β são usados clinicamente há décadas no tratamento de sintomas e patologias como 
arritmias, hipertensão, ansiedade, e insuficiência cardíaca, entre outros. Estudos 
epidemiológicos relativos a vários tipos de cancro têm mostrado que os bloqueadores β 
estão associados a uma diminuição da taxa de mortalidade. Como tal, esforços têm sido 
desenvolvidos no sentido de estudar a eficácia destes fármacos como adjuvantes no 
tratamento do cancro. Curiosamente, os estudos epidemiológicos também têm 
revelado que nem todos os bloqueadores β apresentam este benefício sobre a 
mortalidade e a agressividade dos tumores. Na nossa opinião isso pode dever-se aos 
diferentes perfis farmacológicos destes fármacos. Neste trabalho foram avaliados os 
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efeitos de vários bloqueadores β, com diferentes perfis farmacológicos para alvos 
intracelulares, na biologia de células humanas de cancro do ovário denominadas SKOV-
3. Para este propósito, avaliou-se o efeito dos agonistas AD, NA e isoprenalina (ISO; 
agonista adrenérgico sintético com elevada afinidade para os recetores β) e dos 
antagonistas, propranolol (PRO; não seletivo para os recetores adrenérgicos β ), 
carvedilol (CAR; não seletivo para os recetores adrenérgicos β e seletivo para os α1), 
atenolol (ATE; seletivo para os recetores adrenérgicos β1) e ICI 118,551 (ICI; seletivo 
para os recetores adrenérgicos β2), quando aplicados isoladamente e em combinação 
agonista/antagonista na proliferação e migração destas células. Numa primeira fase do 
trabalho, foram estabelecidas curvas de crescimento da cultura celular durante oito dias 
para caracterizar os parâmetros dinâmicos deste tipo de células. Posteriormente, foram 
realizadas várias experiências com o intuito de determinar os valores de EC50 e IC50, 
respetivamente para o efeito proliferativo e anti-proliferativo dos vários agonistas e 
antagonistas dos recetores adrenérgicos. De todos os agonistas em estudo, apenas a AD 
aumentou significativamente a proliferação das células SKOV-3, a ISO tendencialmente 
aumentou a proliferação destas células e a NA não teve qualquer efeito. No sentido de 
esclarecer quais os subtipos de recetores adrenérgicos que estariam envolvidos no 
aumento da proliferação induzida pelos agonistas, as células foram previamente 
tratadas com diferentes antagonistas, e depois igualmente expostas a estes fármacos 
em simultâneo com os agonistas. À exceção do CAR, todos os antagonistas foram 
capazes de reverter o efeito proliferativo da AD e da ISO. Apesar da NA não ter tido 
efeito por si só na proliferação das células SKOV-3, todos os antagonistas, quando 
aplicados em simultâneo com esta amina foram capazes de reduzir significativamente a 
proliferação destas células. Estes resultados estão de acordo com o facto de estes 
antagonistas terem já sido descritos como agonistas inversos, mostrando a 
complexidade dos seus efeitos na proliferação celular. Este é um dado importante a ter 
em conta no estudo dos efeitos dos bloqueadores β na proliferação celular e noutros 
parâmetros biológicos, uma vez que isto pode explicar a maior ou menor eficácia de 
alguns destes fármacos como adjuvantes no tratamento do cancro. Os nossos resultados 
sugerem que os bloqueadores β diminuem a proliferação das células SKOV-3, mas, tal 
como os agonistas testados, não têm qualquer efeito na migração. De facto, as 
experiências de avaliação da capacidade de migração celular realizadas 6, 24 e 30 horas 
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após os tratamentos com os vários fármacos em estudo (AD, NA, ISO, PRO, ATE, CAR e 
ICI) não mostraram qualquer efeito neste parâmetro. A concentração de CA é cerca de 
10 vezes superior no ovário comparativamente à encontrada em circulação. Alguns 
autores sugerem que isto se deve a uma elevada inervação simpática dos tecidos 
ováricos, que concorre para uma elevada concentração de CA nestes tecidos, mas outros 
referem a possibilidade das células do ovários serem capazes de produzir CA. No sentido 
de esclarecer se as células SKOV-3 produzem estas aminas, realizou-se um estudo piloto 
de quantificação de CA por cromatografia líquida de alta pressão com deteção 
eletroquímica (HPLC-ED). Os resultados mostraram que estas células são capazes de 
produzir NA, mas não AD. A realização de mais experiências permitirá esclarecer estes 
resultados preliminares e desenhar novas metodologias para aprofundar o estudo da 
produção de CA endógenas por células de cancro do ovário, uma vez que novas e 
interessantes perspetivas se adivinham com estes achados. Em conjunto, os nossos 
resultados sugerem que a ativação adrenérgica desempenha um papel importante na 
proliferação das células do cancro do ovário, muito provavelmente através dos 
recetores adrenérgicos β (β1 e β2), dado que, salvo uma exceção, os antagonistas 
utilizados reduziram a proliferação destas células, sendo o PRO (um bloqueador β não 
seletivo) o mais eficaz na reversão dos efeitos da AD. O CAR, o PRO e o ATE têm 
atualmente várias aplicações clinicas. A possibilidade de que estes e outros 
bloqueadores β  possam ser utilizados com outros fins terapêuticos, que não os 
clássicos, torna-se muito atrativa para efeitos comerciais. No entanto, é necessário 
aprofundar o conhecimento relativamente às vias de sinalização adrenérgicas β 
envolvidas na proliferação de células do cancro do ovário, de forma a desenvolver novos 
bloqueadores β com maior seletividade para estas vias, ou aproveitar fármacos já 
comercializados que possam ser úteis para prevenir e/ou tratar este cancro. Novos 
estudos poderão assim passar por investigar as vias de sinalização implicadas nestes 
efeitos através da utilização de inibidores seletivos. Estudos como este podem assim 
contribuir para elucidar quais os bloqueadores β que de forma mais efetiva revertem os 
efeitos proliferativos induzidos pelas CA (libertadas excessivamente por exemplo em 
resposta ao stresse) em células de cancro do ovário, e que consequentemente poderão 
ser usados como estratégias promissoras no tratamento deste tipo de cancro. 
Presentemente, estão a decorrer três estudos clínicos que pretendem avaliar a 
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segurança e a eficácia dos bloqueadores β no tratamento do cancro da mama, colorectal 
e do ovário que vêm assim corroborar a atualidade e o interesse do tema da nossa 
investigação.   
 
Palavras-chave: Stresse, catecolaminas, recetores adrenérgicos, β-bloqueadores, SKOV-
3, proliferação, migração. 
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1. Introduction 
1.1. Cancer 
 
Cancer development begins with the arising of abnormal cells that proliferate beyond 
their usual borders and can invade adjacent parts of the body and spread to other organs 
on a multistep process denominated metastatic process 1.  
 
On 2000, Hanahan & Weinberg defined the six hallmarks of cancer: self-sufficiency in 
growth signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion from 
programmed cell death (cellular apoptosis), limitless replicative potential, sustained 
angiogenesis, invasion and metastasis 1. Some years later, the same researchers 
proposed two new emergent hallmarks: deregulation of cellular energetics and 
avoidance of immune destruction, and two enabling characteristics: genome instability 
and mutation and tumour-promoting inflammation 2.   
 
Many factors might contribute to the development of cancer. These factors include 
individual genetic factors and other internal or external agents, which can act 
simultaneously or sequentially on cancer promotion. About 30% of cancer deaths occur 
due to behavioural and dietary risk factors such as high body mass index, low fruit and 
vegetable intake, lack of physical activity, tobacco use and alcohol abuse. Among these 
risk factors, tobacco use is the most important, being responsible for 20% of global 
cancer deaths and about 70% of global lung cancer deaths 3. Ageing is associated with 
an inability for cellular repair, constituting an important factor for cancer development 
4. Cancer figure among the leading causes of death worldwide, accounting for 8.2 million 
deaths in 2012 3. 
 
As a result of ageing and lifestyle adopted by modern societies an increase on cancer 
incidence within the next two decades from 14 million in 2012 to 22 million is expected 
5. 
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1.2. Ovarian Cancer  
Human ovarian cancer is the seventh most common tumour and the sixth cause of death 
for cancer in woman worldwide (Figure 1). It is also the major cause of death for 
gynaecological cancers 5. This high mortality rate is essentially due to the fact that the 
disease is usually diagnosed at late stages when tumours are already metastasized and 
because there is a lack of effective therapy for advanced disease. This has led to intense 
research efforts to identify effective screening strategies for ovarian cancer, but results 
have been disappointing, particularly with regard to decreases in mortality rates 6.  
 
 
 
Figure 1. Incidence and mortality among different cancers within the economically developed and 
developing countries 5  
 
 
Epidemiology of ovarian cancer includes modifiable and non-modifiable. The main 
modifiable risk factors are those related to diet (e.g. high fat diet 7 and obesity 8) and 
smoking 9. The main non-modifiable risk factors are age 4 and family history 10.  
 
The advances in molecular genetics and the arising of Genome Wide Association Studies 
led to the identification of BRCA1 and BRCA2 gene mutations which predispose to the 
hereditary breast/ovarian cancer syndrome 11. Mutations in mismatch repair genes 
essentially MSH2 and MLH1 which are the most common of all and predispose to Lynch 
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syndrome, are also associated with ovarian cancer occurrence 10. It is also known that 
P53 gene mutation is tightly associated to ovarian cancer arousal 10. The incidence of 
such genetic alterations on ovarian cancer patients makes the detection of this 
mutations very useful to identify risk groups. 
 
1.3. Stress and Allostatic Systems  
 
On 1930, Walter Cannon described for the first time the concepts of homeostasis (a 
complex dynamic equilibrium maintained by all living organisms) and that upon a threat 
the organism activates a “fight or flight” stress response firstly through the activation of 
the sympathetic nervous system (SNS). He also described that adrenal medulla and SNS 
operate as a unit and that adrenaline (AD) is not only the active mediator of the adrenal 
medulla, but also a neurotransmitter in the SNS 12, 13. 
 
The concept of stress was described for the first time by Hans Selye on 1976 as “…the 
nonspecific response of the body to any demand” who also described stressor as “… an 
agent that produces stress any time” 14.   
 
Allostasis, firstly described by Stearling and Eyer on 1988, refers to the process of 
adaptation of the body upon the exposure to various stressors 15. Homeostasis is 
constantly challenged by internal or external factors leading to the release of 
compounds such as hormones and growth factors that induce neuroendocrine and 
behaviour responses 16.  
 
Stress can be acute, when it occurs in a short period of time, or chronic, when it occurs 
repeatedly and/or on a long period of time 17. During the stress response, there is an 
increase on cerebral function, vigilance, heart frequency and attention. Additionally, 
stress-related alterations lead to increased oxygenation and nutrition of the brain, heart 
and skeletal muscles, crucial organs of the stress response and the ‘fight or flight’ 
reaction 18. The organism response to an acute stressor is vital for survival.   If the stress 
response is excessive or prolonged, turning chronic, alterations of physiological events 
may occur, being harmful for the organism, since vital functions are affected including 
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cardiovascular, immune, gastrointestinal and reproductive function, as well as energy 
metabolism, restoration of homeostasis, circadian rhythms and blood pressure 16,17. 
Recent studies have been focused on the idea that the chronic activation of biological 
systems by stress may highly affect cancer progression exerting effects that have impact 
on a variety of important hallmarks of cancer and, thus, on patient survival 19–21.  
 
1.4. Stress Response 
 
Stress response is associated to the activation of two main systems: the sympatho-
adrenomedullary system (SAMS), comprising the sympathetic nervous system (SNS) and 
the adrenal medulla, and the hypothalamic pituitary adrenal axis (HPA). The main 
effector of HPA is cortisol, while SNS involves the release of the catecholamines (CA), 
adrenaline (AD) and noradrenaline (NA) 22.   
 
Catecholamines synthesis 
 
CA are biogenic amines that have a catechol group with an amino group attached. The 
precursor of CA synthesis is L-Tyrosine (Tyr), which can be obtained from diet or by the 
hydroxylation of phenylalanine in the liver 23,24. 
 
Tyr present in adrenal chromaffin cells or neurons is converted to 
dihydroxyphenylalanine (DOPA) by tyrosine hydroxylase (TH), a soluble cytoplasmic 
enzyme, which catalyses the rate-limiting step of CA synthesis. Tetrahydrobiopterin is 
used by TH as cofactor and molecular oxygen to generate three sub-products: DOPA, 
dihydrobiopterin and water 13.  
 
DOPA is then converted into dopamine by a nonspecific enzyme, aromatic L-amino acid 
decarboxylase, also known as DOPA decarboxylase, which uses pyridoxal phosphate as 
cofactor. Subsequently, DA is taken up from the cytoplasm into storage vesicles and 
converted into NA by dopamine-β-hydroxylase. A percentage of this enzyme is released 
simultaneously with AD and NA by exocytosis 23. 
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NA is converted into AD by phenylethanolamine-N-methyltransferase (PNMT), a soluble 
cytoplasmic enzyme that uses S-adenosyl-methionine as cofactor. The main location of 
this enzyme is the adrenal medulla, but it is also present in sympathetic innervated 
organs and some brain areas that are able to synthesize small amounts of AD 13,23,24. 
Figure 2. Pathway for CA biosynthesis. In this pathway, TH catalyses the conversion of the amino acid 
tyrosine to DOPA. Then, DOPA is converted by DOPA decarboxylase to dopamine. Next, dopamine is 
converted to NA in chromaffin granule, by DβH. Finally, in the cytoplasm, NA is converted by PNMT to AD. 
Adapted from Richard Kvetnansky et al, 2009 13. CA – catecholamine; TH - tyrosine hydroxylase; DOPA – 
dihydroxyphenylalanine; NA – noradrenaline; DβH - dopamine-β- hydroxylase; PNMT – 
phenylethanolamine-N-methyltransferase; AD – adrenaline. Adapted from Richard Kvetnansky et al. 
200913 
 
The sympatho-adrenomedullary system 
 
The SNS is organized as a central component, the pre-ganglionic neuron located in the 
spinal cord that communicates with the peripheral component, which is a post-
ganglionic neuron situated in the sympathetic ganglion, through chemical synapses 25. 
 
At synapses within the sympathetic ganglia, pre-ganglionic sympathetic neurons release 
acetylcholine that binds and activates cholinergic receptors (nicotinic and muscarinic) 
on post-ganglionic neurons. In response to this stimulus, post-ganglionic neurons 
release essentially noradrenaline (NA) but also adrenaline (AD)  25. Prolonged activation 
can also elicit the release of AD from the adrenal medulla. Once released, AD and NA 
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bind to adrenergic receptors (AR) on peripheral tissues leading to several effects as pupil 
dilation, increased sweating, increased heart rate and increased blood pressure 25. 
 
1.5. Adrenergic receptors 
 
CA act through interaction with two different classes of AR, termed α and β, activating 
a cascade of reactions that are responsible for all the physiological alterations previously 
mentioned 13.  
 
AR family has several members that correspond to nine different gene products, 
comprised by three types: Type α1 (subtype α1A, α1B, α1C), type α2 (subtype α2A, α2B, 
α2C) and type β (subtype β1, β2, β3) 26, 27. Other two AR candidates were recently 
described (α1L and β4), that may be conformational states of α1A and β1-AR, 
respectively 26. 
 
The AR are composed by seven transmembrane domains and mediate the functional 
effects of catecholamine by coupling to different signaling pathways modulated by G 
proteins 27.  G proteins include 3 types, the stimulatory G proteins of adenylyl cyclase 
(Gs), inhibitory G proteins of adenylyl cyclase (Gi) and the protein coupling α-receptors 
to phospholipase C (Gq) 26. 
 
Adrenergic Drugs 
 
In addition to CA, there are many compounds that interact with AR as agonists and also 
as antagonists, some of them selective to specific types of receptors, being thus used to 
clarify the intracellular pathways involved in their actions (Table 1) 26.  
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Table 1. AR types (α and β) and respective subtypes: α1 (α1A, α1B and α1C), α1 (α2A, α2B and α2C) and 
β1, β2 and β3 and correspondent agonists, antagonists and respective pathways activated for the 
different receptors 28. 
 
α-AR Triggering Pathways 
 
As mentioned, α-AR have 2 subtypes of receptors (α1 and α2) which have different roles. 
 
α1-AR are mainly associated with Gq proteins and their activation triggers both 
phospholipase C and mitogen-activated kinases (MAPK) pathways. Phospholipase C 
leads to the release of inositol 1,4,5-trisphosphate (IP3) and diacylglicerol (DAG) from 
phosphatidilinositol 4,5-bisphosphate (Ptdlns-4,5-P2). IP3 and DAG act as second 
messengers. IP3 stimulates the release of calcium from sequestered stores, which in turn 
activate several kinases and DAG activates protein kinase C. The MAPK pathway is not 
yet clarified, but it seems to mediate the production of cell growth factors and citokines 
29. 
 
α2-AR are mostly coupled to Gi proteins, which inhibit adenylyl cyclase activity and 
consequently decrease intracellular levels of cyclic adenosine monophosphate (cAMP). 
α2-AR are associated with platelet aggregation, contraction of vascular smooth muscle 
Receptor Agonist Antagonist Effects 
α1 
Common to all 
Phenilepinephine, 
Metthoxamine 
Prazosin, Carvedilol ↑IP3,DAG 
α1A  WB4101, prazozin  
α1B  CEC (irreversible)  
α1C  WB4101  
α2 
Common to all Clonidine, BHT920 
Rauwolscine, 
yohimbine 
↑cAMP 
α2A Oxymetazolin  ↑K+ channels 
α2B  Prazosin 
↓Ca2+ 
channels 
α2C  Prazosin 
↓Ca2+ 
channels 
β 
Common to all Isoprenaline Propranolol, Carvedilol ↑cAMP 
β1 Dobutamine Betaxolol, atenolol  
β2 Procaterol, terbutaline 
Butoxamine, 
ICI 118,551 
 
β3 BRL37344   
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and inhibition of insulin release, and also NA and acetylcholine release when located 
pre-synaptically 29. 
 
β-AR Triggering Pathways 
 
The activation of the three subtypes of β-AR is mediated by the stimulatory coupling 
protein Gs. β-AR signaling has been found to regulate multiple cellular processes that 
contribute to the initiation and progression of cancer. The activation of Gs leads to the 
stimulation of adenylyl cyclase that converts ATP into cAMP. This activation modulates 
both PKA and exchange protein activated by adenylyl cyclase (EPAC) pathways, two 
major effector systems that are tightly related to inflammation, angiogenesis and tissue 
invasion, creating optimal conditions for cancer development 30. 
 
Once activated, PKA phosphorylate several target proteins (transcription factors of the 
CREB/ATF and GATA families and β-adrenergic receptor kinase (BARK)) with serine or 
threonine residues. BARK recruit β-arrestin that inhibits β-AR signaling and activates Src 
kinase, ensuing the activation of factors (STAT-3 and FAK) that modulate cell trafficking 
and motility via cytoskeletal dynamics and cellular resistance to apoptosis. Another 
important event is the activation of BAD (Bcl-2 family member) by PKA that can provide 
chemoresistance to cancer cells 30. 
 
Once phosphorylated, EPAC activates Ras-like guanine triphosphatase (Rap1A) which 
induces downstream effects on diverse cellular processes by AP-1 and Ets (via B-
Raf/mitogen-activated protein kinase (B-RAF)), MAP/extracellular signal-regulated 
kinase (MEK1/2) and ERK1/2) family transcription factors 30. 
 
Overall, transcriptional responses induced by β-adrenergic signaling includes up-
regulation of metastasis-associated genes implicated on inflammation, angiogenesis, 
tissue invasion, and epithelial–mesenchymal transition (EMT), and down-regulation of 
the expression of genes related to antitumour immune responses generating optimal 
conditions for cancer progression 30.   
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Figure 3. Main β-adrenergic signalling pathways related to cancer. The stress hormones, AD and NA, bind 
to β-ARs, mediating the activation of adenylyl cyclase via G proteins and resulting on cAMP synthesis. 
cAMP effectors include the activation of both PKA and EPAC. PKA phosphorylates multiple target proteins, 
including transcription factors of the CREB/ATF and GATA families, as well as β-AR kinase (BARK). BARK 
recruitment of β-arrestin inhibits β-AR signalling and activates Src kinase, resulting in activation of 
transcription factors, such as STAT3. In the second via, the activation of EPAC leads to Rap1A-mediated 
activation of the B-Raf/mitogen-activated protein kinase signalling pathway and downstream effects on 
diverse cellular processes, including gene transcription mediated by AP-1 and Ets family transcription 
factors. The general pattern of transcriptional responses induced by β-adrenergic signalling include the 
up-regulation of expression of metastasis-associated genes involved in inflammation, angiogenesis, tissue 
invasion, and the down-regulation of expression of genes facilitating antitumour immune responses. 
Besides the direct effects on β-receptor-bearing tumour cells, β-adrenergic effects on stromal cells in the 
tumour microenvironment generally synergize with direct effects on tumour cells in promoting cancer 
survival, growth and metastatic dissemination. AD – adrenaline; NA – noradrenaline; AR – adrenergic 
receptor; cAMP - cyclic adenosine monophosphate; PKA - Protein kinase A; EPAC - exchange protein 
activated by adenylyl cyclase; CREB - cAMP response element-binding; STAT3 - Signal transducer and 
activator of transcripton-3. Adapted from Steven W. Cole and Anil K. Sood, 2011 30. 
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1.6. Stress and cancer 
 
The association between stress and cancer has been described and well-studied over 
time. The first author purposing an association between stress and cancer was Galen, in 
200 AD. Galen observed that women with a “melancholic” temperament were more 
vulnerable to have cancer than woman with a more “sanguine” temperament 31. 
 
In the last years many clinical an epidemiological studies where performed in order to 
clarify this association. Despite some studies report no association 32, in most of the 
cases evidences show that stress increases the incidence of cancer 20,33,34,35.  
 
CA levels are substantially higher in the ovarian tissue than in circulating plasma and 
play relevant functional roles in follicular development and steroid production 36. This 
suggests that ovarian cancer cells are able to produce CA by themselves 37,38.  
 
β-AR activation in a variety of cancer cell types is linked to different tumourigenic 
processes already documented 39, such as angiogenesis 21, cell proliferation 40, apoptosis 
41, immune response 42, migration 43, invasion 40 and metastasis 20. 
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Figure 4. Stress responses on tumour microenvironment. Stress response results in the activation of ANS 
and the HPA causing the release of AD, NA and cortisol, respectively. These mediators are able to modify 
tumour microenvironment by enhancing cellular proliferation, migration, invasion and angiogenesis 
contributing to tumour progression. ANS - autonomic nervous system; HPA - hypothalamic-pituitary–
adrenal axis; AD – adrenaline; NA – noradrenaline. Adapted from Lutgendorf et al, 2010 17. 
 
 
 
1.7. β-blockers and cancer  
 
Several β-blockers are characterized by their selectivity for the β-AR subtypes and 
intrinsic sympathomimetic activity 39. Carvedilol (CAR), propranolol (PRO) and atenolol 
(ATE), for instance, are β-blockers that have a long history of use for treatment of 
arrhythmia, hypertension, ischemic heart disease, anxiety, and heart failure treatment, 
among others. Recently, new therapeutic options for these drugs have been advanced 
44. 
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Given the high expression of β-AR in tumour cells, and the tight relationship between 
stress response and cancer progression, reported in several studies, epidemiological 
studies have emerged to clarify the association between β-blockers administration and 
oncological patients mortality 45,46. The majority of this studies showed that  oncological 
patients treated with β-blockers presented lower mortality rates comparing to their 
counterparts without these drugs 45,46. 
 
The first evidence that isoprenaline (ISO), a synthetic and nor-selective β-AR agonist, 
promotes a significant increase in the proliferation of lung adenocarcinoma cells arise in 
1989 by Schuler and Cole work 47. It was also demonstrated that this effect was inhibited 
by propranolol, a β-AR antagonist, commonly used in clinical setting 47. After this study, 
other reports have shown that CA (AD, NA and the β-AR synthetic agonist ISO), through 
activation of AR trigger signaling pathways induce cell proliferation in different types of 
cancer such as non-small cell lung carcinoma 48, prostate cancer 43, breast cancer 49 and 
colon cancer40. 
 
The main aim of this thesis was to investigate the role of β-ARs on human ovarian 
adenocarcinoma cell line SKOV-3 proliferation and migration ability. We have studied 
the effect of AR agonists and antagonists on SKOV-3 cells proliferation and migration 
ability per se and also the ability of the several AR antagonists to revert SKOV-3 cells 
proliferation induced by the AR agonists under study. 
 
On the other hand, several reports have presented mixed results for the role of β-AR 
signalling in cell migration, with evidence that inhibition of this class of receptors either 
delays 50,51 or promotes 52 migration ability of cancer cells.  
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2. Materials and Methods 
2.1. Materials 
 
Cell culture: DMEM-F12 medium cell culture (Gibco, Portugal); Fetal Bovine Serum (FBS) 
(St. Louis, MO, USA); Penicillin, Streptomycin, (St. Louis, MO, USA); trypsin-EDTA (Sigma, 
St. Louis, MO, USA). 
 
Assays: Cell Proliferation ELISA BrdU kit (Roche Diagnostics, Portugal); MTT ((3-(4, 5-di-
methyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma, St. Louis, MO, USA). 
 
Compounds: The adrenergic agonists: AD (Adrenaline - L-Adrenaline (+)-bitartrate salt), 
NA (Noradrenaline - L-(−)-Noradrenaline (+)-bitartrate salt monohydrate) and ISO 
(Isoprenaline - (−)-Isoprenaline (+)-bitartrate salt) were purchased from Sigma (St. Louis, 
MO, USA). The β-blockers: PRO (Propranolol - DL-Propranolol hydrochloride), ICI (ICI 
118,551 -  (±)-1-[2,3-(Dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-ethylethyl)amino]-2-
butanol hydrochloride); ATE (Atenolol-(±)-4-[2-Hydroxy-3 
[(1methylethyl)amino]propoxy]benzeneacetamide) were purchased from Sigma (St. 
Louis, MO, USA) and CAR (Carvedilol-1-(9H-Carbazol-4-yloxy)-3-((2-(2-
methoxyphenoxy)ethyl)amino)-2-propanol) was purchased from Enzo Life Sciences, 
Inc., (Farmingdale, NY, USA). 
 
Others: Ethanol and DMSO (Invitrogen Corporation, CA, USA.). 
 
2.2. Cell culture procedures 
 
The experimental cellular model used in this thesis, SKOV-3 human ovarian 
adenocarcinoma cell line, was kindly provided by Professor Marco Cosentino from the 
University of Insubria, Varese, Italy.   
 
SKOV-3 cells were maintained in DMEM-F12 medium, supplement with 10% FBS, 100 
U/mL penicillin and 100µg/mL streptomycin. Cells were maintained at 37ºC in a 
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humidified atmosphere of 5% CO2 and 95% air. Medium was changed each 2-3 days. 
After 90% of confluence, corresponding to 3-4 days after seeding, cells were sub-
cultured. The covering medium was removed and the monolayer of cells was washed 
once with 3mL PBS 10x. Next, cells were treated with 1mL of trypsin-EDTA (0.25% (w/v)) 
for approximately 2 minutes to provide cell detachment and provide subsequent sub-
culturing. Cells were cultured in plastic cell culture flasks (25cm2, TPP). 
 
For experimental studies , SKOV-3 cells were seeded into 96-well plates (0.37 cm2, Ø 6.9 
mm, TPP) for MTT and BrdU assays and into 24-well plastic cell culture clusters (2cm2 Ø 
16mm; TPP) for the wound healing assay. All the experiments were performed 72 hours 
after initial seeding. 
 
2.3. Treatments 
 
In order to study the effects of the AR agonists AD, NA and ISO on SKOV-3 cells 
proliferation and migration, cells were incubated for 24 hours with these drugs at 
different concentrations (10 µM for migration and 1 µM for proliferation). For the 
experiments with the β-blockers, cells were pre-treated with PRO at 10 µM (a non-
selective β-AR), CAR at 5 µM (a non-selective β and selective α1), ATE at 10 µM (a selective 
β1-AR) and ICI at 10 µM (a selective β2-AR) for 45 minutes prior to treatment with AD, NA 
or ISO for proliferation and for migration cells were treated with all the β-blockers at 10 
µM. 
 
The agonists under study (AD, ISO, NA) were solved in H2O, and the antagonists PRO and 
ATE in ethanol (0.1% (v/v)) and CAR and ICI in DMSO (0.1% (v/v)). Each solvent was 
solved in culture FBS-medium free and positive control was FBS-medium. 
 
The several β-blockers used in this work were selected by their prevalent use in clinical 
settings, and also for their different affinity for β-AR and ability to modulate specific 
signalling pathways. 
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2.4. Cell Growth Curves 
 
2.4.1. Trypan blue exclusion assay 
 
Cell viability was determined by Trypan Blue exclusion assay and subsequent 
experiments were performed only when viability was higher than 90%. In brief, cells 
were trypsinized and stained with 0.4% Trypan blue. Viable cells were counted with a 
hemocytometer. 
 
For growth curves, SKOV-3 cells were plated in 96-well plate at 1.0x104 cells/ml and 
counted (two squares for each well) every day, during 8 days. The population doubling 
time (PDT) is the interval, calculated during the logarithmic phase of growth, in which 
cells double in number. This parameter was calculated by the following formula: DT = T 
ln2/ ln (Xe / Xs): T is the incubation time; Xb is the cell number at the beginning of the 
incubation time and Xe is the cell number at the end of the incubation time. 
 
2.4.2. MTT assay 
 
The MTT assay is based on mitochondrial dehydrogenase activity. Mitochondrial 
dehydrogenases of viable cells cleave the tetrazolium ring, yielding purple formazan 
crystals, which are insoluble in aqueous solutions. The amount of produced products is 
determined spectrophotometrically. Initially, SKOV-3 cells were seeded into 96-well 
plates at a density of 1×104 cells/well and incubated for 12 hours with DMEM-F12 
supplemented with antibiotics 1% plus 10% FBS to allow cell attachment. From this 
moment, the MTT assay was performed each 24 hours until the growth curve plateau 
phase. Cells were exposed to MTT solution (5 mg/ml) for 3 hours and then lysed with 
200 µl DMSO. Absorbance was measured at 550 and 650 nm. All samples were assayed 
in quadruplicated and in two independent experiments, and the mean value for each 
experiments was calculated. The results are given as absorbance. 
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2.5. Determination of EC50 and IC50 values 
 
For determination of the half maximal inhibitory concentration (IC50), the concentration 
that reduces the effect under study by 50%, and the half maximal effective 
concentration (EC50) values, the concentration that gives half maximal response, cells 
were seeded into 96-well plates at a density of 1×104 cells/well for 72 hours, then 
incubated for 12 hours with DMEM-F12 serum free (to synchronize the cell cycle) and 
then incubated for 24 hours with increasing concentrations of the various compounds 
(0.1, 1, 5, 10, 20, 50 and 100 µM). The assay was performed according to Juranic et al., 
2005 53. SKOV-3 cells were incubated with MTT solution (5 mg/ml) for 3 hours and then 
lysed with 200 µM DMSO. Absorbance was measured at 550 and 650 nm. All samples 
were assayed in triplicated and at least in three independent experiments, and the mean 
value for each experiments was calculated. The results are given as mean (± SEM) and 
expressed as percentage of control. 
 
2.6. Cell proliferation studies 
 
For the treatment of cells with the various adrenergic ligands, 1x104 cells per well were 
seeded in 96-well plates and incubated for 72 hours. The medium was supplemented 
with 1% antibiotics plus 10% FBS. Then, cells were starved in serum-free medium for 12 
hours to synchronize cell cycle. After these incubation periods, cells were next incubated 
with AD, NA or ISO at 1 µM for 24 hours to study the effect of these adrenergic agonists 
over cellular proliferation. To examine the effects of various β-blockers on proliferation, 
cells were pre-treated with or without the several adrenergic antagonists, PRO (10µM), 
CAR (5 µM), ATE (10 µM) and ICI (10 µM) for 45 minutes prior to and also simultaneously 
with the adrenergic agonists.   After the several treatments, cellular proliferation was 
assessed both by bromodeoxyuridine (BrdU) incorporation and MTT assays.  
 
2.6.1. Incorporation of 5' bromodeoxyuridine (BrdU)  
 
The incorporation of 5’bromodeoxyuridine assay is a method based on the 
incorporation of BrdU, a thymidine analogue, instead of thymidine into DNA of 
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proliferating cells. After its incorporation into DNA, BrdU is detected by an 
immunoassay. Given several technical difficulties and to the lack of reproducibility of 
results with this method, the MTT assay was performed as an alternative method to 
BrdU. 
 
2.6.2. MTT assay 
 
The protocol used to evaluate the effect of the several drugs under study on cellular 
proliferation through a MTT assay was similar to what was described in section 2.4.2. 
 
2.7. Cell Migration studies 
 
2.7.1. Wound healing assay 
In order to evaluate migration of SKOV-3 cells after exposure to several drugs, a wound 
healing assay was performed. Initially, cells were plated in 24-well plates and grown till 
confluence. A sterile tip was used to create a scratch in the cell layer. Wounded 
monolayers were washed twice with 500 μL of PBS (1x), to remove floating cells, and 
subsequently treated with the several compounds in serum-free medium. Cells were 
then treated with 10 μM of AD, NA, ISO, PRO, CAR, ATE and ICI and respective controls. 
 
Images were taken at 0, 6, 24 and 30 hours after treatment to evaluate wound closure. 
Wound areas were calculated using Image J 1.47v software at different time points. The 
percentage of wound closure was calculated as the wound area at a given time 
compared to the initial wound surface.  
 
All treatments were assayed in duplicated and in four independent experiments. 
Migration was expressed as the average ± SEM of the difference between the initial 
width of the wound (at time 0) and the width registered after 6, 24 and 30 h 
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2.8. Determination of catecholamine content 
 
CA cellular content were determined by high pressure liquid chromatography with 
electrochemical detection (HPLC-ED) using the methodology described by Soares-da-
Silva et al 54. 
 
2.8.1. High pressure liquid chromatography with electrochemical 
detection assay  
 
The HPLC system consists in a pump (Gilson model 302; Gilson Medical Electronics, 
Villiers le Bel, France) connected to a manometer (Gilson model 802 C) and an ODS 5 μm 
steel column (Biophase; Bioanalytical Systems, West Lafayette, IN, USA), 25 cm long. The 
samples were injected by an automatic injector (Gilson model 321), connected to a 
Gilson diluter (model 401). The mobile phase consisted in a degassed solution of citric 
acid (0.1 mM), 1-octanesulfonic acid sodium salt (OSA) (0.5 mM), 
ethylenediaminetetraacetic acid (EDTA) (0.17 mM), dibutylamine (1mM), methanol (8% 
v/v) and was adjusted to pH 3.5 with perchloric acid, being pumped at a rate of 1 ml/min. 
The CA detection was performed electrochemically with a carbon electrode, an 
electrode Ag/AgCl and an amperometric detector (Gilson model 141). The detector cell 
was adjusted to 0.75 V. The originated current was monitored via software Gilson HPLC 
172. The lower limits of CA detection varied from 350 to 1000 fmol. 
 
 
2.9. Statistical analysis 
 
Results are expressed as percentage of control and presented as mean ± SEM. 
Comparison between treatments was performed using SPSS Statistics software 21 
version. For the calculation of EC50 and IC50 values, the parameters of the Hill equation 
were fitted to the experimental data by using a nonlinear regression analysis. The 
normality of data distribution and the homogeneity of variances were evaluated by 
Shapiro-Wilk’s and Levene’s tests, respectively. For proliferation studies one-way 
analysis of variance (ANOVA) and nonparametric Kruskal-Wallis test were performed 
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followed by Bonferroni’s test. Migration experiments were statistically assessed by 
factorial repeated measures ANOVA, followed by Bonferroni’s test. A right-tailed 
logarithmic transformation was performed, when data distribution was not normal. 
Statistical significance was accepted when p<0.05. All experiments performed in this 
study were repeated at least in three independent times. 
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3. Results 
The main aim of this study was to clarify the role of the stress hormones, AD and NA, 
(and of ISO, a synthetic adrenergic agonist) and β-blockers in ovarian cancer cells 
proliferation and migration by using a human ovarian adenocarcinoma cell line (SKOV-
3). Thus, the involvement of β1 and β2-AR in ovarian cancer cells biology was 
investigated by using selective agonists and antagonists for these receptors. 
 
3.1.  SKOV-3 cells growth curves 
 
In order to identify the adequate time point within the exponential growth phase of 
SKOV-3 cells to be used in subsequent studies, cells were seeded at 1x104cells/ml in a 
96-well plate and their growth curves were determined by trypan blue (Figure 5.A) 
exclusion and MTT assays (Figure 5.B). 
 
 Both assays were performed each 24 hours as represented on figure 5, A and B.  The 
population doubling time (PDT) was approximately 34 hours, and 72 hours of culture the 
adequate time point within the exponential growth phase to use in the subsequent 
experiments. 
  
Figure 5. Growth curves for human ovarian adenocarcinoma SKOV-3 cells. Cells were seeded on a 96-well 
plate at 1.0x104 cells/mL and maintained in DMEM-F12 medium supplemented with 10% of FBS and 1% 
penicillin/streptomycin. Cell proliferation was assessed by MTT assay each 24 hours for 7 days (A) and by 
trypan blue exclusion assay (B) each 24 hours for 8 days. Population doubling time is 34 hours. Error bars 
represent mean of absorbance/cell concentration ± SEM. 
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3.2.  Determination of EC50 and IC50 values 
 
3.2.1. Determination of EC50 values for agonists 
 
 In order to determine the EC50 values of AR agonists in this cellular model, SKOV-3 cells 
were treated in control conditions (without drugs) and with increasing concentrations 
(0.1, 1, 5, 10, 20, 50 and 100 μM) of AD (Figure 6.A), NA (Figure 6.B) and ISO (Figure 6.C) 
for 24 hours to determine the effects of these drugs on cellular growth. The above 
experiments generated concentration-response curves for all agonists. None of the 
agonists-induced increase of cell proliferation was dependent of concentration (Pearson 
coefficients 0.281, 0.294 and 0.304 for AD, NA and ISO, respectively). NA significantly 
increased proliferation at 0.1 to 20 μM. Higher concentrations of the drug (50 and 100 
μM) had no effect on SKOV-3 cells proliferation. NA and ISO had a similar effect, 
increasing proliferation at 0.1 to 50 μM. At 100 μM NA and ISO had no effect on cell 
proliferation. 
Figure 6. Effect of AD (A), NA (B) and ISO (C) on cell growth of SKOV-3 cells assessed by MTT assay after 
24 hours of treatment. Results are expressed as mean ± SEM and normalized to 100% of control groups 
(without drugs). AD – adrenaline; NA – noradrenaline; ISO – isoprenaline. 
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3.2.2. Determination of IC50 values for β-blockers 
 
In order to calculate the IC50 values for the effect of β-blockers on cellular proliferation, 
cells were treated under control conditions (without drugs) and with increasing 
concentrations of either PRO, CAR, ATE or ICI (0.1, 1, 5, 10, 20, 50 and 100 μM) for 24 
hours. The concentration-response curves of SKOV-3 cells proliferation are shown in 
Figure 7 and IC50 values in Table 3. The concentration-response curves of cell 
proliferation are shown in Figure 7 and IC50 values in Table 3. The IC50 value for ATE 
was 10.15 μM, 16.88 μM for CAR and for ICI 118,551 the IC50 value was 13.10 μM. PRO 
was proved to be the most potent β-blocker with an IC50 of 7.92 μM.  
 
 
 
Figure 7. Concentration-response curves for SKOV-3 cell proliferation. Cells were treated with increasing 
concentrations (0, 0.1, 1, 5, 10, 20, 50 and 100 μM) of PRO (A), ATE (B), CAR (C) and ICI (D) for 24 hours 
and proliferation was assessed by MTT assay. Results are expressed as percentage of control and 
presented as mean ± SEM. *p<0.05 comparing to control. PRO – propranolol; ATE – atenolol; CAR - 
carvedilol; ICI - ICI 118,551 
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3.3.  Effect of β-blockers on SKOV-3 cells proliferation 
 
To clarify the role of β-AR upon SKOV-3 cell proliferation induced by AR activation, the 
agonists AD, NA and ISO at 1 μM were employed alone and simultaneously with PRO (10 
μM), a non-selective β-AR antagonist, ATE (10 μM) to elucidate the role of β1-AR, CAR 
(5 μM), a potent non-selective β and selective α1-AR antagonist, or ICI (10 μM), a β2-AR 
selective antagonist. The effect of β-blockers per se was also evaluated. The 
concentrations used for β-blockers were selected based on the IC50 values, previously 
calculated. 
 
3.3.1. Effect of agonists and antagonists per se on cell proliferation 
 
The effects of agonists and antagonists per se on cell proliferation are represented on 
figure 8, A and B respectively. AD at 1 µM significantly increased cell proliferation to 131 
± 10 % (n=12, p=0.036) and ISO at 1 µM showed a tendency to increase cell proliferation 
to 144 ± 16 % (n=12, p=0.051), whereas NA had no effect. In respect to AR antagonists, 
only CAR at 5 μM was able to significantly decrease cell proliferation to 77 ± 6 % (n=12, 
p=0.013).  
 
 
 
 
 
Table 2. IC50 values for β-blockers on SKOV-3 cells proliferation. 
Cell type β-Blockers IC50 (µM) 95% n 
 
 
SKOV-3 
Atenolol 10.15 2.778-13.333 12 
Propranolol 7.92 4.196-13.84 12 
Carvedilol 16.88 4.391-39.14 9 
ICI118,551 13.10 5.694-16.96 9 
Shown are IC50 values with the corresponding 95% confidence intervals. 
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3.3.2. β-blockers influence on adrenaline effect 
 
The role of β-AR in cell proliferation is supported by the next results. Figure 9 shows the 
effect of the four β-blockers under study on SKOV-3 cells proliferation induced by AD (1 
μM). The increase of proliferation induced by AD was markedly reduced by PRO at 10 
μM to 42 ± 5 % (n=12, p<0.001), to 63 ± 8 % (n=12, p=0.004) by ATE at 10 μM and to 63 
± 7 % (n=12, p=0.004) by ICI (10µM). CAR at 5 μM had no effect on cell proliferation 
(n=12, p=0.105). 
 
 
 
 
Figure 8. Effect of agonists AD, NA and ISO at 1 µM (A) and antagonists PRO, ATE and ICI at 10 µM and CAR 
at 5 µM (B) on SKOV-3 cells proliferation. Cells were treated with each drug for 24 hours and cell 
proliferation was measured by MTT assay, as described in the Materials and Methods section. Agonists 
control group was H2O (100 µM), PRO and ATE control group was ethanol (100 µM), CAR and ICI control 
group was ethanol (100 µM). AD – adrenaline; NA – noradrenaline; ISO – isoprenaline; PRO – propranolol; 
ATE – atenolol; ICI – ICI118,551; CAR – carvedilol.  Results are expressed as percentage of control and 
presented as mean ± SEM. *p<0.05 comparing to control group. #p=0.051 
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3.3.3. β-blockers influence on noradrenaline effect 
 
The effect of the four β-blockers under study on SKOV-3 cells proliferation induced by 
NA (1 μM) is shown on figure 10. As it shows, cell proliferation increase induced by NA 
was markedly reduced by all the β-blockers under study. PRO at 10 μM was able to 
decrease cell proliferation induced by NA to 61 ± 7 % (n=12, p<0.001), CAR at 5 μM to 
65 ± 6 % (n=12, p<0.001), ATE at 10 μM to 62 ± 6 % (n=12, p<0.001) and ICI at 10 µM to 
39 ± 5 % (n=12, p<0.001). 
 
 
 
Figure 9. Effect of PRO (10 μM), CAR (5 μM), ATE (10 μM) and ICI (10 μM) on AD (1 μM) induced SKOV-3 
cell proliferation. Cells were pre-treated with the different β-blockers for 45 minutes before incubation 
simultaneously with AD for 24 hours. Cell proliferation was measured by MTT assay, as described in the 
Materials and Methods section. **p <0.01, significantly different from the AD-treated group *** p<0.001, 
significantly different from the AD treated group. AD – adrenaline; PRO – propranolol; ATE – atenolol; ICI 
– ICI 118,551; CAR – carvedilol.  Results are expressed as percentage of control and presented as mean ± 
SEM. 
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3.3.4. β-blockers influence on isoprenaline effect 
 
The effect of the β-blockers on SKOV-3 cells proliferation induced by ISO 1 μM can be 
seen on figure 11. Cell proliferation increase induced by ISO was highly reduced by all 
the β-blockers under study. PRO at 10 μM significantly decreased cell proliferation to 61 
± 7 % (n=12, p<0.001), CAR at 5 μM to 59 ± 6 % (n=12, p<0.001), ATE at 10 μM to 62 ± 5 
% (n=12, p<0.001) and ICI (10µM) to 51 ± 7 % (n=12, p<0.001). 
 
 
 
 
 
 
Figure 10. Effect of PRO (10 μM), CAR (5 μM), ATE (10 μM) and ICI (10 μM) on NA (1 μM) induced SKOV-
3 cell proliferation. Cells were pre-treated with the different β-blockers for 45 minutes before incubation 
simultaneously with NA for 24 hours. Cell proliferation was measured by MTT assay, as described in the 
Materials and Methods section. ***p <0.001, significantly different from the NA treated group. NA – 
noradrenaline; PRO – propranolol; ATE – atenolol; ICI – ICI118,551; CAR – carvedilol.  Results are 
expressed as percentage of control and presented as mean ± SEM. 
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In our study, with the exception of CAR, all the β-blockers tested were able to revert the 
proliferative effect of the adrenergic agonists under study. These results approve the 
hypothesis that the activation of both β1-AR and β2-AR have a crucial role on the 
activation of SKOV-3 cells proliferation pathways. 
  
Figure 11. Effect of PRO (10 μM), CAR (5 μM), ATE (10 μM) and ICI (10 μM) on SKOV-3 cell proliferation 
induced by ISO 1 μM. Cells were pre-treated with the different β-blockers for 45 minutes before 
incubation simultaneously with ISO for 24 hours. Cell proliferation was measured by MTT assay, as 
described in the Materials and Methods section. ***p <0.0001, significantly different from the ISO-
treated group. ISO – isoprenaline; PRO – propranolol; ATE – atenolol; ICI – ICI 118,551; CAR – carvedilol.  
Results are expressed as percentage of control and presented as mean ± SEM. 
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3.1.  Effect of chronic treatment (24 hours) with adrenergic agonists and β- 
blockers on SKOV-3 cells Migration  
 
To evaluate the impact of adrenergic agonists and β-blockers on SKOV-3 cells migration 
a wound healing assay was performed. On figures 12 and 13 are representative panels 
of each treatment for each different considered time point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 12. Migratory ability of SKOV-3 cells after exposure to adrenergic agonists, evaluated by a wound 
healing assay. A scratch was made with a sterile tip in a confluent layer of cells. Then cells were treated 
with AD, NA and ISO at 10 µM and a control group. Wound closure was observed at 6, 24 and 30 hours 
after treatment (n=8). The yellow line corresponds to perimeter immediately after treatment. Scale bar 
corresponds to 400 µm. AD – adrenaline; NA – noradrenaline; ISO – isoprenaline. 
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Figure 13. Migratory ability of SKOV-3 cells after exposure to β-blockers, evaluated by a wound healing 
assay. A scratch was made with a sterile tip in a confluent layer of cells. Then cells were treated with CAR, 
ICI, ATE and PRO at 10 µM and the respective control groups. Wound closure was observed after 6, 24 
and 30 hours after treatment (n=6-8). The yellow line corresponds to perimeter immediately after 
treatment. Scale bar corresponds to 400 µm. CAR – carvedilol; ICI – ICI 118,551; ATE – atenolol; PRO - 
propranolol. 
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As we can observe in figure 14 none of the tested drugs had a significant effect upon 
SKOV-3 cell migration. On table 4 the wound closure (%) is represented at different time 
points (6, 24 and 30 hours) comparing to 0 hours after treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 14. Migratory ability of SKOV-3 cells, evaluated by a wound healing assay. A scratch was made 
with a sterile tip in a confluent layer of cells and wound closure was observed after 6, 24 and 30 hours 
after treatment with agonists at 10 µM and respective control (A) ICI and CAR at 10 µM and respective 
control (B) and ATE and PRO at 10 µM and respective control group with (n=4-8). Results are expressed 
as percentage of control and presented as mean ± SEM. Differences were not statistically significant. AD 
– adrenaline; NA – noradrenaline; ISO – isoprenaline CAR – carvedilol; ICI – ICI 118,551; ATE – atenolol; 
PRO - propranolol. 
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3.2. Determination of catecholamine content by high pressure liquid 
chromatography with electrochemical detection  
 
In order to study whether or not SKOV-3 cells are able to produce CA, a preliminary assay 
was made by high pressure liquid chromatography with electrochemical detection 
(HPLC-ED). After 4 days in culture, SKOV-3 cells were incubated overnight with percloric 
acid (0.2 M) and afterwards CA content was assessed by HPLC-ED. As we can see in Table 
5, SKOV-3 are able to produce NA but not AD or DA. Results are expressed as peak 
height.  
 
 
 
 
  
 
Cell type 
 
L-DOPA 
 
AD 
 
DA 
 
NA 
 
SKOV-3 
 
- 
 
- 
 
- 
1308 
(n=2) 
 
Table 3.  Catecholamine cellular release of SKOV-3 cells.  
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4. Discussion 
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4. Discussion  
The association between stress and cancer has been described and well-studied over 
time and evidence seem to support that stress increases the incidence of cancer 
20,33,34,35. In the last years many clinical and epidemiological studies where performed in 
order to clarify this association. However, the molecular and cellular mechanisms by 
which stress increases the risk of cancer and their prognosis remain understudied. 
 
Endogenous CA seem to mediate the association between stress response and poor 
cancer outcomes 55. These amines through interaction with β-AR modulate cancer cell 
microenvironment 17. In a variety of cancer cell types the activation of these receptors 
affect several tumorigenic processes 39 including angiogenesis 21, cell proliferation 40, 
apoptosis 41, immune response 42, migration 43, invasion 40 and metastasis 20, is already 
documented. 
 
β-blockers are presently used to treat hypertension, angina, migraine and anxiety, as 
well as cardiac arrhythmias and cardiac failure, among others 44. Recently, several 
epidemiological studies have associated a lower mortality rate among oncological 
patients using  β-blockers  45,46.  
 
The direct effects of stress hormones in ovarian cancer are not well characterized. CA 
are particularly abundant in the ovary, playing relevant functional roles in follicular 
development and steroid production 36. This suggests that ovarian cancer cells are able 
to endogenously produce CA 37,38. Interestingly enough, preliminary results presented in 
this thesis show that SKOV-3 cells produce NA.  
 
On the other hand, the expression of β-AR has been identified in ovarian cancer cells, 
including SKOV3 cells 21, 56. In some ovarian cancer cell lines, including SKOV-3 cells, 
stress related mediators (AD and NA) through β-AR can directly enhance the production 
of the proangiogenic cytokine vascular endothelial growth factor (VEGF) 21. The same 
authors purposed in subsequent investigations that CA mediate the invasive potential 
of ovarian cancer cells 56 and that it can be due to STAT-3 pathway activation 55. These 
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effects are also dependent on β-AR activation once PRO abolished the invasive potential 
55,56. More recent evidences support that ovarian cancer cells exposed to both AD and 
NA exhibit lower levels of anoikis, by activating FAK 57, which is involved in the 
modulation of cell trafficking and motility via cytoskeletal dynamics, as well as cellular 
resistance to apoptosis (e.g. anoikis). PKA-dependent activation of Bcl-2 family member 
BAD can also render cancer cells resistant to chemotherapy-induced apoptosis 30. 
 
In vivo and in vitro studies showed that proliferation of human colon adenocarcinoma 
is enhanced by AD 19,40,41 and NA 19. A finding also observed by our group in the same 
type of cells (unpublished results). Other evidences also show that β-AR activation by 
ISO increases proliferation and migration of prostate cancer cell lines 43.  
 
In the present work, the effect of the stress hormones AD, NA and ISO, a synthetic β 
non-selective agonist, and several β-blockers, on proliferation and migration, two 
hallmarks in cancer progression, of ovarian adenocarcinoma cells SKOV-3, was 
evaluated.Our results confirmed that adrenergic agonists affect ovarian cancer cells 
proliferation. In fact, AD significantly augmented proliferation of SKOV-3 cells, and ISO 
showed a tendency to increase cell proliferation, similarly to previous studies in other 
cancer cell lines 40,46,48. On the other hand, NA had no effect on proliferation of this cell 
type, contrarily to preceding evidences in human colon adenocarcinoma 19 and in human 
oral squamous cell carcinoma cells 42. Nevertheless, our results are somehow in 
accordance with the fact that both AD and ISO have a high affinity for β-AR, ISO 
particularly for β2-AR, strongly expressed in SKOV-3 cells 21.  
 
Based on the above findings, we explored the AR subtypes through which the adrenergic 
agonists acted, by using β-blockers with distinct AR targets. Altogether, the results 
suggest that β-AR had a prominent role in this process. The β-blockers under study 
significantly reverted the proliferation induced by all the agonists, reinforcing that the 
agonists mainly acted through β-AR. In addition, results clearly indicate the involvement 
of both β-AR subtype’s β1 and β2 in promoting ovarian cancer cell proliferation. PRO, 
the nonselective β-AR antagonist, was the most potent β-blocker in reverting AD effects 
upon SKOV-3 cells proliferation, probably by its ability to bind to both β1 and β2, as it 
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was already described for colon adenocarcinoma 19,40. Indeed, the proliferation increase 
evoked by AD was equally abolished by ATE and ICI, drugs also able to diminish the 
proliferation of colon adenocarcinoma promoted by AD 19. CAR was not able to 
significantly affect the proliferation increase evoked by AD. 
 
The β2-AR involvement on SKOV-3 cells proliferation was tested using ICI, a β2-AR 
selective antagonist. All the β-blockers inhibited the proliferation induced by ISO, and 
ICI was the most potent, suggesting that the effect of ISO was mainly due to interaction 
with β2-AR as  it was proposed for prostate cancer cells 43.  
 
All the β-blockers similarly reduced cell proliferation when applied simultaneously with 
NA, unlike preceding evidences in colon adenocarcinoma 19, whereas NA per se had no 
effect on cell proliferation. Nevertheless, this finding suggests that even in basal 
conditions of proliferation, the simultaneous presence of adrenergic antagonists with 
the agonists influences specific intracellular pathways.  
 
Indeed, β-blockers are not exclusive antagonists for the G-protein pathways, but they 
may independently modulate more than one pathway behaving as partial agonist, 
inverse agonists or pure antagonists in each pathway, increasing the complexity of their 
actions 59. Thus, biased agonism might have outstanding implications for β-AR blockers 
therapeutic use in cancer, since distinct signalling through these pathways is thought to 
have specific functional consequences 59.  
 
All the β-AR blockers tested were already recognized as being inverse agonists 60. The 
finding that CAR used alone was able to decrease SKOV-3 cells proliferation, suggests an 
inverse agonism action, a characteristic that was already described for other cell types 
61. CAR is able to activate different signalling pathways depending on the cell type 61, but 
its effect upon SKOV-3 cells proliferation was unknown. 
 
The β2 selective antagonist (ICI) had no effect on  proliferation when used alone, despite 
its ability to diminish cAMP levels 61. Thus, as already suggested by other researchers, β-
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blockers seems to have complex profiles for cAMP modulation and Erk1/2 activation at 
both β1 and β2-AR 44. 
 
The downstream signalling pathways involved in β-AR mediated tumour growth are the 
main focus of several researchers. ERK is the best studied and the deregulation of this 
pathway occurs in approximately one-third of all human cancers 62. Some studies have 
concluded that β-AR mediated ERK1/2 activation could be one of the mechanisms 
underlying stress-induced cancer cell growth for several cancer cell types including 
breast 49, haemangioma-derived endothelial cells 58 and colon adenocarcinoma 19  
suggesting that β-AR blockade may be an effective approach for patients with stress-
related cancer. On the other hand, there are also evidences in prostate cancer cells that 
ISO through binding to β2-AR leads to the activation of a G protein-independent ERK 
pathway, but dependent on β-arrestin 43. Definitely, the pathway whereby growth 
factors and mitogens activate ERK signalling has particular relevance to cancer biology 
knowledge. All the β-blockers used in our study, with the exception of ICI, were already 
described as being capable to activate ERK pathway. However, as referred before, when 
used alone, only CAR was able to decrease cell proliferation. 
 
Several reports have presented mixed results for the role of β-AR signalling in cell 
migration, with evidence showing that β-AR blockade either delays 50,51 or promotes 52 
migration ability of cancer cells. We sought to determine if similar effects on cell 
migration could be observed in SKOV-3 cells treated whit different agonists and β-
blockers. None of the tested drugs had influence on SKOV-3 cells migration. 
 
Preliminary results have shown that SKOV-3 cells are able to produce NA an interesting 
finding that needs further exploration.  
 
CAR, PRO and ATE have actually many clinical applications. The discovery that these and 
other β-blockers can be used for new clinical applications is very attractive for 
commercial purposes, once their effects are well studied. Anyway, it is crucial to extend 
the knowledge of β-signalling pathways involved in cancer to select appropriate 
inhibitors that can prevent and possibly treat cancer. In addition, corroborating  the 
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putative use of β-blockers as therapeutic agents in cancer, three clinical studies are 
currently running with the pretension of assessing the safety and efficacy of β-blockers 
in breast, colorectal and ovarian cancers 63. 
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5. Final Considerations and Future 
work 
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5. Final Considerations and Future work 
This work revealed that among the AR agonists tested only AD significantly increased 
the proliferation of SKOV-3 cells, whereas ISO showed a tendency to increase this 
proliferation. Among the β-blockers used, only CAR was not able to reduce AD induced 
increases on proliferation. PRO was the most potent in this effect, confirming the role 
of both β1 and β2-AR subtypes in cancer biology. The reversion of cell proliferation 
induced by ISO was more effective with ICI, confirming the preferential involvement of 
β2-AR. 
  
This study reinforces several lines of evidence suggesting that stress hormones have an 
important role in carcinogenesis, namely in SKOV-3 cells and that β-blockers can be used 
to revert these effects. Migration was affected by none of the tested drugs.  
 
Cancer cell proliferation is a complex process that involves several pathways and 
different molecules; therefore further approaches are essential to evaluate other β-
blockers, and also the intracellular mechanisms underlying the effect of endogenously 
CA, greatly released under stress conditions, but also of adrenergic agonists in clinical 
use. A better knowledge about these mechanisms might contribute to the discovery of 
new promising targets for cancer prevention and treatment. 
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